XM does not provide services to residents of the United States of America.
Z
Z

Zimmer


News

U.S. Alight, Mastercard, Visa

U.S. RESEARCH ROUNDUP-Alight, Mastercard, Visa Aug 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alight, Mastercard and Visa, on Tuesday. HIGHLIGHTS * Alight Inc ALIT.N : JP Morgan cuts to neutral from overweight * Biomarin Pharmaceutical Inc BMRN.O : Bernstein raises to outperform from market-perform * Liquidia Corp LQDA.O : Raymond James raises to strong buy from outperform * Mastercard MA.N : JP Morgan raises
A
A
B
D
P
P
V
A
D
T
A
E
F
G
Z
B
D

Zimmer Biomet Holdings Inc reports results for the quarter ended in June - Earnings Summary

Zimmer Biomet Holdings Inc reports results for the quarter ended in June - Earnings Summary Zimmer Biomet Holdings Inc ZBH.N reported quarterly adjusted earnings of $2.01​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.82. The mean expectation of twenty seven analysts for the quarter was for earnings of $1.99 per share.
Z

Zimmer Biomet beats profit estimates on strong demand for medical devices

Zimmer Biomet beats profit estimates on strong demand for medical devices Aug 7 (Reuters) - Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures. Medical device makers have boosted investor expectations in the recent quarters as more people, especially older Americans, opt for non-urgent surgeries such as hip and knee replacements.
S
Z

Zimmer Biomet Signs Definitive Agreement To Acquire OrthoGrid Systems, Inc.

BRIEF-Zimmer Biomet Signs Definitive Agreement To Acquire OrthoGrid Systems, Inc. Aug 7 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET SIGNS DEFINITIVE AGREEMENT TO ACQUIRE ORTHOGRID SYSTEMS, INC. Source text for Eikon: ID:nPn2rpgcxa Further company coverage: ZBH.N
Z

Shopify soars as AI focus powers quarterly beat, bullish forecast

UPDATE 4-Shopify soars as AI focus powers quarterly beat, bullish forecast Adds details from call in paragraphs 4, 7, 12, analyst comment in paragraph 4, updates share movement in paragraph 1 Aug 7 (Reuters) - Shopify SHOP.TO beat analysts' estimates for second-quarter results and forecast upbeat sales growth on Wednesday as its AI-enabled tools attracted more merchants to its e-commerce services, sending its shares up more than 20%.
Z

Zimmer Biomet Q2 Adjusted EPS USD 2.01 Vs. IBES Estimate USD 1.99

BRIEF-Zimmer Biomet Q2 Adjusted EPS USD 2.01 Vs. IBES Estimate USD 1.99 Aug 07 (Reuters) - Zimmer Biomet Q2 net income USD 242.8 million. Q2 EPS USD 1.18 Q2 sales USD 1,942 million vs. IBES estimate USD 1,941 million outlook FY adjusted EPS USD 8-8.15
Z

BOJ eases market migraine, Super Micro aches

MORNING BID AMERICAS-BOJ eases market migraine, Super Micro aches A look at the day ahead in U.S. and global markets from Mike Dolan In an extraordinary round trip over the past week, world markets have rebounded sharply from days of turbulence - thanks in part to Bank of Japan almost apologising on Wednesday for its role in the ruckus - and traders now try to figure out what's next.
M
N
U
J
U
U
U
F
U
Z
A

U.S. STOCKS Synchrony Financial, Crypto Stocks, Industrial REITs

BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Crypto Stocks, Industrial REITs Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq tumbled more than 2% to a two-week low on Wednesday, pulled down as megacap chip and tech stocks fell on the prospect of tighter China-focused U.S.
A
C
E
I
M
N
X
U
U
Z

Some medical device makers rise, while others tip lower after J&J results

BUZZ-Some medical device makers rise, while others tip lower after J&J results ** Some medical device manufacturers rise after Johnson & Johnson's JNJ.N results, while others fall ** Zimmer Biomet ZBH.N rise 2.9% to $110.58, Medtronic MDT.N gain 2.45% to $80.01, Abbott ABT.N rise 2.10% to $104.90, Stryker SYK.N up 1.04% at $336.90 ** Shares of Intu
A
C
S
Z

Australia's Osteopore surges on exclusive distribution agreement

BUZZ-Australia's Osteopore surges on exclusive distribution agreement ** Shares of medical technology firm Osteopore OSX.AX rise as much as 35.7% to A$0.076 ** Stock hits highest level, and posts its biggest intraday pct gain since June 6 ** Co says it signed an exclusive distribution agreement with a unit of Singapore-based Zimmer Biomet ZBH.N **
Z

Zimmer Biomet Holdings On June 28, Got Into A New Five-Year Revolving Credit Agreement & New 364-Day Revolving Credit Agreement

BRIEF-Zimmer Biomet Holdings On June 28, Got Into A New Five-Year Revolving Credit Agreement & New 364-Day Revolving Credit Agreement July 1 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET HOLDINGS: ON JUNE 28, GOT INTO A NEW FIVE-YEAR REVOLVING CREDIT AGREEMENT & NEW 364-DAY REVOLVING CREDIT AGREEMENT ZIMMER BIOMET HOLDINGS INC: FIVE-
Z

U.S. AT&T, ATI, California Resources

U.S. RESEARCH ROUNDUP-AT&T, ATI, California Resources July 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AT&T, ATI and California Resources, on Monday. HIGHLIGHTS * AT&T Inc T.N : JP Morgan adds stock to its U.S. analyst focus list * ATI Inc ATI.N : JP Morgan removes stock from its U.S.
A
I
N
W
H
Z
T
U

RevelAi Health And Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement To Advance Value-Based Care And Health Equity Through Powered Technology

BRIEF-RevelAi Health And Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement To Advance Value-Based Care And Health Equity Through AI-Powered Technology June 12 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : REVELAI HEALTH AND ZIMMER BIOMET ANNOUNCE EXCLUSIVE MULTI-YEAR CO-MARKETING AGREEMENT TO ADVANCE VALUE-BASED CARE AND HEALTH EQ
Z



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.